These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 6155278)

  • 1. The use of R(+)-ADTN in dopamine receptor binding assays.
    Davis A; Poat JA; Woodruff GN
    Eur J Pharmacol; 1980 May; 63(2-3):237-8. PubMed ID: 6155278
    [No Abstract]   [Full Text] [Related]  

  • 2. [3H] 2-Amino-6,7-dihydroxy 1,2,3,4-tetrahydronapthalene (ADTN): a potential specific dopamine receptor ligand.
    Clement-Cormier Y; Abel M
    Res Commun Chem Pathol Pharmacol; 1978 Oct; 22(1):15-25. PubMed ID: 725314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in guanine nucleotide sensitive and insensitive 3H-ADTN binding in striatum following substantia nigra lesions.
    Hirschhorn ID; Makman MH; Gardner EL
    Eur J Pharmacol; 1980 Mar; 62(1):123-4. PubMed ID: 6154585
    [No Abstract]   [Full Text] [Related]  

  • 4. Selective storage in vivo of 5,6-ADTN in dopamine-rich areas of the rat brain.
    Westerink BH; Dijkstra D; Feenstra MG; Horn AS; Rollema H
    Eur J Pharmacol; 1980 Jun; 64(2-3):115-21. PubMed ID: 7398758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The conformation of dopamine at its receptor: binding of monohydroxy-2-aminotetralin enantiomers and positional isomers.
    Tedesco JL; Seeman P; McDermed JD
    Mol Pharmacol; 1979 Sep; 16(2):369-81. PubMed ID: 514252
    [No Abstract]   [Full Text] [Related]  

  • 6. Retina contains guanine nucleotide sensitive and insensitive classes of dopamine receptors.
    Makman MH; Dvorkin B; Horowitz SG; Thal LJ
    Eur J Pharmacol; 1980 May; 63(2-3):217-22. PubMed ID: 6155277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of dopamine agonist and antagonist binding sites in mammalian retina.
    Makman MH; Dvorkin B; Horowitz SG; Thal LJ
    Brain Res; 1980 Aug; 194(2):403-18. PubMed ID: 6770965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of ADTN (2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene) as a ligand for brain dopamine receptors [proceedings].
    Cross AJ; Crow TJ; Owen F
    Br J Pharmacol; 1979 May; 66(1):87P. PubMed ID: 454971
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of ADTN and various other 2-aminotetralin derivatives on the efflux of 3H-dopamine from rat striatal slices.
    Mulder AH; Braakhuis B; De Regt V; Dijkstra D; Horn AS
    Eur J Pharmacol; 1980 Jun; 64(4):349-55. PubMed ID: 7389827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADTN (2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene): a prototype for possible dopaminergic false transmitters?
    Roberts PJ; Davis A
    Adv Biochem Psychopharmacol; 1978; 19():177-91. PubMed ID: 696460
    [No Abstract]   [Full Text] [Related]  

  • 11. The significance of COMT activity in controlling dopamine agonist levels in brain and serum: studies with a prodrug and a metabolite of 6,7-ADTN.
    Rollema H; Westerink BH; Mulder TB; Dijkstra D; Feenstra MG; Horn AS
    Eur J Pharmacol; 1980 Jun; 64(4):313-23. PubMed ID: 7389825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine receptor binding regulated by guanine nucleotides.
    Creese I; Usdin TB; Snyder SH
    Mol Pharmacol; 1979 Jul; 16(1):69-76. PubMed ID: 481426
    [No Abstract]   [Full Text] [Related]  

  • 13. Dopamine receptor binding of 3H-ADTN (2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene) regulated by guanyl nucleotides.
    Creese I; Snyder SH
    Eur J Pharmacol; 1978 Aug; 50(4):459-61. PubMed ID: 699970
    [No Abstract]   [Full Text] [Related]  

  • 14. [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalen (ADTN). Regional distribution and in vivo binding after acute and chronic drug treatment.
    Clement-Cormier Y; Smith CE
    Neurochem Res; 1980 Jun; 5(6):641-51. PubMed ID: 7402434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereospecific binding of 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene to rat brain dopamine receptors [proceedings].
    Davis A; Poat JA; Woodruff GN
    Biochem Soc Trans; 1979 Feb; 7(1):147-8. PubMed ID: 437261
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats.
    Pycock CJ; Kerwin RW; Carter CJ
    Nature; 1980 Jul; 286(5768):74-6. PubMed ID: 7393327
    [No Abstract]   [Full Text] [Related]  

  • 17. A neuroblastoma clone which has dopamine-sensitive adenylate cyclase but which lacks stereospecific binding sites for the neuroleptic [3H]spiperone.
    Hartley EJ; Spuhler K; Prasad KN; Seeman P
    Brain Res; 1980 May; 190(2):574-7. PubMed ID: 6154511
    [No Abstract]   [Full Text] [Related]  

  • 18. Further characterization of structural requirements for agonists at the striatal dopamine D-1 receptor. Studies with a series of monohydroxyaminotetralins on dopamine-sensitive adenylate cyclase and a comparison with dopamine receptor binding.
    Seiler MP; Markstein R
    Mol Pharmacol; 1982 Sep; 22(2):281-9. PubMed ID: 7144729
    [No Abstract]   [Full Text] [Related]  

  • 19. Stereospecific antagonism by d-butaclamol of dopamine-induced relaxation of the isolated rabbit mesenteric artery.
    Brodde OE; Freistühler J; Meyer FJ
    J Cardiovasc Pharmacol; 1981; 3(4):828-37. PubMed ID: 6167812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-dependent interaction of benzamides with dopamine receptors in rat and dog anterior pituitary glands.
    Stefanini E; Clément-Cormier Y; Vernaleone F; Devoto P; Marchisio AM; Collu R
    Neuroendocrinology; 1981 Feb; 32(2):103-7. PubMed ID: 6163103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.